Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

AVANTHIKA THANUSHI WYNN

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1124306006
CMS profile
1078613
Location
ATLANTA, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$47.15

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $47.15 1

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Amgen Inc. $47.15 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

AVANTHIKA THANUSHI WYNN

NPI 1124306006 · CMS profile ID 1078613

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

ATLANTA, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1124306006?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
AVANTHIKA THANUSHI WYNN, NPI 1124306006, CMS profile ID 1078613. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1124306006?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). AVANTHIKA THANUSHI WYNN, NPI 1124306006, CMS profile ID 1078613. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1124306006?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
AVANTHIKA THANUSHI WYNN, NPI 1124306006, CMS profile ID 1078613, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1124306006?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $47.15 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $47.1510/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020541005 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2023 $47.15 1
PY2024 $119.54 1
PY2025 $292.71 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $61,289.70 17
PY2024 Principal investigator $119,323.70 119

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

119 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Dompe Farmaceutici S.p.A. $80.00 11/04/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457196
Principal investigator 1 Dompe Farmaceutici S.p.A. $396.00 11/04/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457198
Principal investigator 1 Dompe Farmaceutici S.p.A. $143.00 11/04/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457200
Principal investigator 1 Dompe Farmaceutici S.p.A. $2,112.00 11/04/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457202
Principal investigator 1 Dompe Farmaceutici S.p.A. $40.00 11/04/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457204
Principal investigator 1 Dompe Farmaceutici S.p.A. $40.00 11/04/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457206
Principal investigator 1 Dompe Farmaceutici S.p.A. $1,056.00 11/04/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457208
Principal investigator 1 Dompe Farmaceutici S.p.A. $143.00 11/04/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457210
Principal investigator 1 Dompe Farmaceutici S.p.A. $143.00 10/18/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457240
Principal investigator 1 Dompe Farmaceutici S.p.A. $827.00 10/18/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457242
Principal investigator 1 Dompe Farmaceutici S.p.A. $310.00 10/18/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457244
Principal investigator 1 Dompe Farmaceutici S.p.A. $496.00 10/18/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457246
Principal investigator 1 Dompe Farmaceutici S.p.A. $119.00 10/18/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457248
Principal investigator 1 Dompe Farmaceutici S.p.A. $94.00 10/18/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457250
Principal investigator 1 Dompe Farmaceutici S.p.A. $222.00 10/18/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457252
Principal investigator 1 Dompe Farmaceutici S.p.A. $714.00 10/18/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457254
Principal investigator 1 Dompe Farmaceutici S.p.A. $363.00 10/18/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457256
Principal investigator 1 Dompe Farmaceutici S.p.A. $273.00 10/18/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457258
Principal investigator 1 Dompe Farmaceutici S.p.A. $300.00 10/18/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457260
Principal investigator 1 Dompe Farmaceutici S.p.A. $414.00 10/18/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457262
Principal investigator 1 Dompe Farmaceutici S.p.A. $252.00 10/18/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457264
Principal investigator 1 Dompe Farmaceutici S.p.A. $143.00 10/18/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457266
Principal investigator 1 Dompe Farmaceutici S.p.A. $508.25 09/11/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457328
Principal investigator 1 Dompe Farmaceutici S.p.A. $708.70 09/11/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457330
Principal investigator 1 Dompe Farmaceutici S.p.A. $508.25 09/11/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457332
Principal investigator 1 Dompe Farmaceutici S.p.A. $708.70 09/11/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457334
Principal investigator 1 Dompe Farmaceutici S.p.A. $508.25 09/11/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457336
Principal investigator 1 Dompe Farmaceutici S.p.A. $1,748.00 09/11/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457338
Principal investigator 1 Dompe Farmaceutici S.p.A. $708.70 09/11/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457340
Principal investigator 1 Dompe Farmaceutici S.p.A. $94.00 09/11/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457342
Principal investigator 1 Dompe Farmaceutici S.p.A. $74.00 09/11/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457344
Principal investigator 1 Dompe Farmaceutici S.p.A. $2,552.00 09/11/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457346
Principal investigator 1 Dompe Farmaceutici S.p.A. $682.00 09/11/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457348
Principal investigator 1 Dompe Farmaceutici S.p.A. $98.00 09/11/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457350
Principal investigator 1 Dompe Farmaceutici S.p.A. $806.00 09/11/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457352
Principal investigator 1 Dompe Farmaceutici S.p.A. $833.00 09/11/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457354
Principal investigator 1 Dompe Farmaceutici S.p.A. $658.00 09/11/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457356
Principal investigator 1 Dompe Farmaceutici S.p.A. $518.00 09/11/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457358
Principal investigator 1 Dompe Farmaceutici S.p.A. $833.00 09/11/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457360
Principal investigator 1 Dompe Farmaceutici S.p.A. $121.00 09/11/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457362
Principal investigator 1 Dompe Farmaceutici S.p.A. $546.00 09/11/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457364
Principal investigator 1 Dompe Farmaceutici S.p.A. $107.00 09/11/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457366
Principal investigator 1 Dompe Farmaceutici S.p.A. $396.00 09/11/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457368
Principal investigator 1 Dompe Farmaceutici S.p.A. $200.00 09/11/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457370
Principal investigator 1 Dompe Farmaceutici S.p.A. $238.00 08/02/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457306
Principal investigator 1 Dompe Farmaceutici S.p.A. $119.00 08/02/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457308
Principal investigator 1 Dompe Farmaceutici S.p.A. $155.00 08/02/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457310
Principal investigator 1 Dompe Farmaceutici S.p.A. $62.00 08/02/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457312
Principal investigator 1 Dompe Farmaceutici S.p.A. $98.00 08/02/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457314
Principal investigator 1 Dompe Farmaceutici S.p.A. $124.00 08/02/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457316
Principal investigator 1 Dompe Farmaceutici S.p.A. $188.00 08/02/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457318
Principal investigator 1 Dompe Farmaceutici S.p.A. $74.00 08/02/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457320
Principal investigator 1 Dompe Farmaceutici S.p.A. $63.00 08/02/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457322
Principal investigator 1 Dompe Farmaceutici S.p.A. $91.00 08/02/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457324
Principal investigator 1 Dompe Farmaceutici S.p.A. $50.00 08/02/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457326
Principal investigator 1 Dompe Farmaceutici S.p.A. $143.00 07/26/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457304
Principal investigator 1 Dompe Farmaceutici S.p.A. $940.50 07/24/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457372
Principal investigator 1 Dompe Farmaceutici S.p.A. $1,748.00 07/24/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457374
Principal investigator 1 Dompe Farmaceutici S.p.A. $1,748.00 07/24/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457376
Principal investigator 1 Dompe Farmaceutici S.p.A. $1,748.00 07/24/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457378
Principal investigator 1 Dompe Farmaceutici S.p.A. $708.70 07/24/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457380
Principal investigator 1 Dompe Farmaceutici S.p.A. $1,527.60 07/24/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457382
Principal investigator 1 Dompe Farmaceutici S.p.A. $1,427.85 07/24/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457384
Principal investigator 1 Dompe Farmaceutici S.p.A. $1,627.35 07/24/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457386
Principal investigator 1 Dompe Farmaceutici S.p.A. $708.70 07/24/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457388
Principal investigator 1 Dompe Farmaceutici S.p.A. $1,627.35 07/24/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457390
Principal investigator 1 Dompe Farmaceutici S.p.A. $1,748.00 07/24/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457392
Principal investigator 1 Dompe Farmaceutici S.p.A. $1,527.60 07/24/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457394
Principal investigator 1 Dompe Farmaceutici S.p.A. $1,198.90 07/24/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457396
Principal investigator 1 Dompe Farmaceutici S.p.A. $1,427.85 07/24/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457398
Principal investigator 1 Dompe Farmaceutici S.p.A. $1,627.35 07/24/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457400
Principal investigator 1 Dompe Farmaceutici S.p.A. $708.70 07/24/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457402
Principal investigator 1 Dompe Farmaceutici S.p.A. $708.70 07/24/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457404
Principal investigator 1 Dompe Farmaceutici S.p.A. $708.70 07/24/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457406
Principal investigator 1 Dompe Farmaceutici S.p.A. $1,627.35 07/24/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457408
Principal investigator 1 Dompe Farmaceutici S.p.A. $708.70 07/24/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457410
Principal investigator 1 Dompe Farmaceutici S.p.A. $708.70 07/24/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457412
Principal investigator 1 Dompe Farmaceutici S.p.A. $1,627.35 07/24/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457414
Principal investigator 1 Dompe Farmaceutici S.p.A. $1,748.00 07/24/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457416
Principal investigator 1 Dompe Farmaceutici S.p.A. $1,198.90 07/24/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457418
Principal investigator 1 Dompe Farmaceutici S.p.A. $361.00 07/24/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457420
Principal investigator 1 Dompe Farmaceutici S.p.A. $508.25 06/19/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457484
Principal investigator 1 Dompe Farmaceutici S.p.A. $508.25 06/19/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457486
Principal investigator 1 Dompe Farmaceutici S.p.A. $508.25 06/19/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457488
Principal investigator 1 Dompe Farmaceutici S.p.A. $1,427.85 06/19/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457490
Principal investigator 1 Dompe Farmaceutici S.p.A. $1,627.35 06/19/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457492
Principal investigator 1 Dompe Farmaceutici S.p.A. $1,627.35 06/19/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457494
Principal investigator 1 Dompe Farmaceutici S.p.A. $1,198.90 06/19/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457496
Principal investigator 1 Dompe Farmaceutici S.p.A. $708.70 06/05/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457446
Principal investigator 1 Dompe Farmaceutici S.p.A. $708.70 06/05/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457448
Principal investigator 1 Dompe Farmaceutici S.p.A. $1,527.60 06/05/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457450
Principal investigator 1 Dompe Farmaceutici S.p.A. $1,627.35 06/05/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457452
Principal investigator 1 Dompe Farmaceutici S.p.A. $1,527.60 06/05/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457454
Principal investigator 1 Dompe Farmaceutici S.p.A. $1,427.85 06/05/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457456
Principal investigator 1 Dompe Farmaceutici S.p.A. $1,748.00 06/05/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457458
Principal investigator 1 Dompe Farmaceutici S.p.A. $4,224.00 06/03/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457476
Principal investigator 1 Dompe Farmaceutici S.p.A. $143.00 06/03/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457478
Principal investigator 1 Dompe Farmaceutici S.p.A. $143.00 06/03/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457480
Principal investigator 1 Dompe Farmaceutici S.p.A. $940.50 04/05/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457422
Principal investigator 1 Dompe Farmaceutici S.p.A. $940.50 04/05/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457424
Principal investigator 1 Dompe Farmaceutici S.p.A. $1,427.85 04/05/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457426
Principal investigator 1 Dompe Farmaceutici S.p.A. $1,627.35 04/05/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457428
Principal investigator 1 Dompe Farmaceutici S.p.A. $1,527.60 04/05/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457430
Principal investigator 1 Dompe Farmaceutici S.p.A. $1,198.90 04/05/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457432
Principal investigator 1 Dompe Farmaceutici S.p.A. $932.90 04/05/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457434
Principal investigator 1 Dompe Farmaceutici S.p.A. $1,627.35 04/05/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457436
Principal investigator 1 Dompe Farmaceutici S.p.A. $1,627.35 04/05/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457438
Principal investigator 1 Dompe Farmaceutici S.p.A. $1,198.90 04/05/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457440
Principal investigator 1 Dompe Farmaceutici S.p.A. $932.90 04/05/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457442
Principal investigator 1 Dompe Farmaceutici S.p.A. $1,198.90 04/05/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457444
Principal investigator 1 Dompe Farmaceutici S.p.A. $726.00 04/05/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457460
Principal investigator 1 Dompe Farmaceutici S.p.A. $3,300.00 04/05/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457462
Principal investigator 1 Dompe Farmaceutici S.p.A. $726.00 04/05/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457464
Principal investigator 1 Dompe Farmaceutici S.p.A. $2,494.00 04/05/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457466
Principal investigator 1 Dompe Farmaceutici S.p.A. $1,320.00 04/05/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457468
Principal investigator 1 Dompe Farmaceutici S.p.A. $1,500.00 04/05/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457470
Principal investigator 1 Dompe Farmaceutici S.p.A. $143.00 04/05/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457472
Principal investigator 1 Dompe Farmaceutici S.p.A. $1,056.00 04/05/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457474
Principal investigator 1 Dompe Farmaceutici S.p.A. $16,236.00 02/07/2024 Covered Recipient Teaching Hospital
Emory University Hospital
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154457482